68088 Federal Register / Vol. 70, No. 216 / Wednesday, November 9, 2005 / Notices 

States Attorney for the Southern District 

of Indiana, 10 West Market, Suite 2100, 

Indianapolis, Indiana 46204, and at U.S. 

EPA Region 5, 77 West Jackson 

Boulevard, Chicago, IL 60604. During 

the public comment period, the consent 

decrees may also be examined on the 

following Department of Justice Web 

site, http://www.usdoj.gov/enrd/

open.html. A copy of the Consent 

Decree may also be obtained by mail 

from the Consent Decree Library, P.O. 

Box 7611, U.S. Department of Justice, 

Washington, DC 20044–7611, or by 

faxing a request to Tonia Fleetwood, fax 

no. (202) 514–0097, phone confirmation 

number (202) 514–1547. In requesting a 

copy, please refer to the referenced case 

and enclose a check in the amount of 

$18.25 (25 cents per page reproduction 

costs), payable to the U.S. Treasury.

William D. Brighton, 

Assistant Chief, Environmental Enforcement 

Section, Environment and Natural Resources 

Division.

[FR Doc. 05–22362 Filed 11–8–05; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

[Docket No. DEA–259F] 

Controlled Substances: Final Revised 

Aggregate Production Quotas for 2005

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice.

ACTION: Notice of final aggregate 

production quotas for 2005. 

SUMMARY: This notice establishes final 

2005 aggregate production quotas for 

controlled substances in Schedules I 

and II of the Controlled Substances Act 

(CSA). The DEA has taken into 

consideration comments received in 

response to a notice of the proposed 

revised aggregate production quotas for 

2005 published August 5, 2005 (70 FR 

45432).

EFFECTIVE DATE: November 9, 2005.

FOR FURTHER INFORMATION CONTACT:

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

Drug Enforcement Administration, 

Washington, DC 20537, Telephone: 

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in Schedules I and II. This 

responsibility has been delegated to the 

Administrator of the DEA by 28 CFR 

0.100. The Administrator, in turn, has 

redelegated this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

The 2005 aggregate production quotas 

represent those quantities of controlled 

substances in Schedules I and II that 

may be produced in the United States in 

2005 to provide adequate supplies of 

each substance for: The estimated 

medical, scientific, research and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks (21 U.S.C. 826(a) and 21 

CFR 1303.11). These quotas do not 

include imports of controlled 

substances. 

On August 5, 2005, a notice of the 

proposed revised 2005 aggregate 

production quotas for certain controlled 

substances in Schedules I and II was 

published in the Federal Register (70 

FR 45432). All interested persons were 

invited to comment on or object to these 

proposed aggregate production quotas 

on or before August 26, 2005. 

Nine companies commented on a total 

of 21 Schedules I and II controlled 

substances within the published 

comment period. One company 

questioned the aggregate production 

quota for marihuana. Eight companies 

proposed the aggregate production 

quotas for alfentanil, amphetamine, 

codeine (for conversion), difenoxin, 

dihydromorphine, diphenoxylate, 

fentanyl, hydrocodone, hydromorphone, 

levo-desoxyephedrine, methadone, 

methadone intermediate, 

methylphenidate, morphine (for sale), 

oxycodone, pentobarbital, remifentanil, 

sufentanil, tetrahydrocannabinols, and 

thebaine were insufficient to provide for 

the estimated medical, scientific, 

research, and industrial needs of the 

United States, for export requirements 

and for the establishment and 

maintenance of reserve stocks. 

DEA has taken into consideration the 

above comments along with the relevant 

2004 year-end inventories, initial 2005 

manufacturing quotas, 2005 export 

requirements, actual and projected 2005 

sales, research, product development 

requirements and additional 

applications received. Based on this 

information, the DEA has adjusted the 

final 2005 aggregate production quotas 

for alfentanil, cathinone, 

dihydromorphine, diphenoxylate, levoalphacetylmethadol, levodesoxyephedrine, methadone, 

methadone intermediate, oxycodone, 

pentobarbital and sufentanil to meet the 

legitimate needs of the United States. 

Regarding amphetamine, codeine (for 

conversion), difenoxin, fentanyl, 

hydrocodone, hydromorphone, 

marihuana, methylphenidate, morphine 

(for sale), remifentanil, 

tetrahydrocannabinols and thebaine the 

DEA has determined that the proposed 

revised 2005 aggregate production 

quotas are sufficient to meet the current 

2005 estimated medical, scientific, 

research, and industrial needs of the 

United States and to provide for 

adequate inventories. 

Therefore, under the authority vested 

in the Attorney General by section 306 

of the Controlled Substances Act of 

1970 (21 U.S.C. 826), and delegated to 

the Administrator of the DEA by § 0.100 

of Title 28 of the Code of Federal 

Regulations, and redelegated to the 

Deputy Administrator, pursuant to 

§ 0.104 of Title 28 of the Code of Federal 

Regulations, the Deputy Administrator 

hereby orders that the 2005 final 

aggregate production quotas for the 

following controlled substances, 

expressed in grams of anhydrous acid or 

base, be established as follows:

Basic Class—Schedule I 

Final Revised 

2005 Quotas

(g) 

2,5–Dimethoxyamphetamine 2,801,000 

2,5–Dimethoxy-4-

ethylamphetamine (DOET) 2 

2,5–Dimethoxy-4-(n)-

propylthiophenethylamine 10 

3–Methylfentanyl ................... 2 

3–Methylthiofentanyl ............. 2 

3,4–

Methylenedioxyamphetamine (MDA) .......................... 15 

3,4–Methylenedioxy-Nethylamphetamine (MDEA) 5 

3,4–

Methylenedioxymethamphetamine (MDMA) ............... 17 

3,4,5–

Trimethoxyamphetamine ... 2 

4–Bromo-2,5-

dimethoxyamphetamine 

(DOB) ................................ 2 

4–Bromo-2,5-

dimethoxyphenethylamine 

(2–CB) ............................... 2 

4–Methoxyamphetamine ...... 5 

4–Methylaminorex ................ 2 

4–Methyl-2,5-

dimethoxyamphetamine 

(DOM) ............................... 2 

5–Methoxy-3,4-

methylenedioxyamphetamine ..................................... 2 

5–Methoxy-N,Ndiisopropyltryptamine (5–

MeO-DIPT) ........................ 10 

Acetyl-alpha-methylfentanyl .. 2 

Acetyldihydrocodeine ............ 2 

Acetylmethadol ..................... 2 

Allylprodine ........................... 2 

Alphacetylmethadol .............. 2 

Alpha-ethyltryptamine ........... 2 

Alphameprodine .................... 2 

Alphamethadol ...................... 3 

Alpha-methyltryptamine 

(AMT) ................................ 10 

Federal Register / Vol. 70, No. 216 / Wednesday, November 9, 2005 / Notices 68089

Basic Class—Schedule I 

Final Revised 

2005 Quotas

(g) 

Alpha-methylfentanyl ............ 2 

Alpha-methylthiofentanyl ...... 2 

Aminorex ............................... 2 

Benzylmorphine .................... 2 

Betacetylmethadol ................ 2 

Beta-hydroxy-3-

methylfentanyl ................... 2 

Beta-hydroxyfentanyl ............ 2 

Betameprodine ..................... 2 

Betamethadol ........................ 2 

Betaprodine .......................... 2 

Bufotenine ............................. 2 

Cathinone ............................. 3 

Codeine-N-oxide ................... 252 

Diethyltryptamine .................. 2 

Difenoxin ............................... 5,000 

Dihydromorphine .................. 2,046,000 

Basic Class—Schedule I 

Final Revised 

2005 Quotas

(g) 

Dimethyltryptamine ............... 3 

Gamma-hydroxybutyric acid 8,000,000 

Heroin ................................... 2 

Hydromorphinol .................... 2 

Hydroxypethidine .................. 2 

Lysergic acid diethylamide 

(LSD) ................................. 61 

Marihuana ............................. 4,500,000 

Mescaline .............................. 2 

Methaqualone ....................... 5 

Methcathinone ...................... 4 

Methyldihydromorphine ........ 2 

Morphine-N-oxide ................. 252 

N,N-Dimethylamphetamine ... 2 

N-Ethylamphetamine ............ 2 

Basic Class—Schedule I 

Final Revised 

2005 Quotas

(g) 

N-Hydroxy-3,4-

methylenedioxyamphetamine ..................................... 2 

Noracymethadol .................... 2 

Norlevorphanol ..................... 52 

Normethadone ...................... 2 

Normorphine ......................... 12 

Para-fluorofentanyl ............... 2 

Phenomorphan ..................... 2 

Pholcodine ............................ 2 

Propiram ............................... 50,000 

Psilocybin .............................. 2 

Psilocyn ................................ 7 

Tetrahydrocannabinols ......... 312,500 

Thiofentanyl .......................... 2 

Trimeperidine ........................ 2 

Basic Class—Schedule II 

Proposed Revised 

2005 Quotas

(g) 

1–Phenylcyclohexylamine .............................................................................................................................................................. 2 

Alfentanil ........................................................................................................................................................................................ 2,800 

Alphaprodine .................................................................................................................................................................................. 2 

Amobarbital .................................................................................................................................................................................... 2 

Amphetamine ................................................................................................................................................................................. 14,500,000 

Cocaine .......................................................................................................................................................................................... 228,000 

Codeine (for sale) .......................................................................................................................................................................... 39,605,000 

Codeine (for conversion) ............................................................................................................................................................... 55,000,000 

Dextropropoxyphene ...................................................................................................................................................................... 167,365,000 

Dihydrocodeine .............................................................................................................................................................................. 750,000 

Diphenoxylate ................................................................................................................................................................................ 833,000 

Ecgonine ........................................................................................................................................................................................ 73,000 

Ethylmorphine ................................................................................................................................................................................ 2 

Fentanyl ......................................................................................................................................................................................... 1,428,000 

Glutethimide ................................................................................................................................................................................... 2 

Hydrocodone (for sale) .................................................................................................................................................................. 37,604,000 

Hydrocodone (for conversion) ....................................................................................................................................................... 1,500,000 

Hydromorphone ............................................................................................................................................................................. 3,300,000 

Isomethadone ................................................................................................................................................................................ 2 

Levo-alphacetylmethadol (LAAM) .................................................................................................................................................. 3 

Levomethorphan ............................................................................................................................................................................ 2 

Levorphanol ................................................................................................................................................................................... 5,000 

Meperidine ..................................................................................................................................................................................... 9,753,000 

Metazocine ..................................................................................................................................................................................... 1 

Methadone (for sale) ..................................................................................................................................................................... 17,940,000 

Methadone Intermediate ................................................................................................................................................................ 20,334,000 

Methamphetamine [700,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,615,000 

grams for methamphetamine mostly for conversion to a Schedule III product; and 45,000 grams for methamphetamine 

(for sale)] .................................................................................................................................................................................... 2,360,000

Methylphenidate ............................................................................................................................................................................. 35,000,000

Morphine (for sale) ........................................................................................................................................................................ 35,000,000 

Morphine (for conversion) .............................................................................................................................................................. 110,774,000 

Nabilone ......................................................................................................................................................................................... 2 

Noroxymorphone (for sale) ............................................................................................................................................................ 1,002 

Noroxymorphone (for conversion) ................................................................................................................................................. 4,000,000 

Opium ............................................................................................................................................................................................ 1,280,000 

Oxycodone (for sale) ..................................................................................................................................................................... 50,490,000 

Oxycodone (for conversion) .......................................................................................................................................................... 920,000 

Oxymorphone ................................................................................................................................................................................ 534,000 

Pentobarbital .................................................................................................................................................................................. 20,335,000 

Phencyclidine ................................................................................................................................................................................. 2,006 

Phenmetrazine ............................................................................................................................................................................... 2 

Racemethorphan ........................................................................................................................................................................... 2 

Remifentanil ................................................................................................................................................................................... 1,800 

Secobarbital ................................................................................................................................................................................... 2 

Sufentanil ....................................................................................................................................................................................... 4,500 

Thebaine ........................................................................................................................................................................................ 72,453,000 

68090 Federal Register / Vol. 70, No. 216 / Wednesday, November 9, 2005 / Notices 

The Deputy Administrator further 

orders that aggregate production quotas 

for all other Schedules I and II 

controlled substances included in 

§§ 1308.11 and 1308.12 of Title 21 of the 

Code of Federal Regulations remain at 

zero. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

Schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $117,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets.

Dated: November 3, 2005. 

Michele M. Leonhart, 

Deputy Administrator.

[FR Doc. 05–22287 Filed 11–8–05; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Office of Justice Programs 

Agency Information Collection 

Activities: Proposed Collection; 

Comments Requested

ACTION: 30-Day Notice of Information 

Collection Under Review 2006 Census 

of Adult Parole Supervising Agencies. 

The Department of Justice (DOJ), 

Office of Justice Programs (OJP) has 

submitted the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

The proposed information collection is 

published to obtain comments from the 

public and affected agencies. This 

proposed information collection was 

previously published in the Federal 

Register Volume 70, Number 161, page 

48981 on August 22, 2005, allowing for 

a 60 day comment period. 

The purpose of this notice is to allow 

for an additional 30 days for public 

comment until December 9, 2005. This 

process is conducted in accordance with 

5 CFR 1320.10. 

Written comments and/or suggestions 

regarding the items contained in this 

notice, especially the estimated public 

burden and associated response time, 

should be directed to the Office of 

Management and Budget, Office of 

Information and Regulatory Affairs, 

Attention Department of Justice Desk 

Officer, Washington, DC 20503. 

Additionally, comments may be 

submitted to OMB via facsimile to (202) 

395–5806. Written comments and 

suggestions from the public and affected 

agencies concerning the proposed 

collection of information are 

encouraged. Your comments should 

address one or more of the following 

four points: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

• Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

• Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

• Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

(1) Type of Information Collection:

Reinstatement, with change, of a 

previously approved collection for 

which approval has expired. 

(2) Title of the Form/Collection: 2006 

Census of Adult Parole Supervising 

Agencies. 

(3) Agency form number, if any, and 

the applicable component of the 

Department sponsoring the collection:

Form: CJ–36. Corrections Statistics, 

Bureau of Justice Statistics, Office of 

Justice Programs, United States 

Department of Justice. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: State Departments of 

Corrections or State Parole authority. 

Others: The Federal Bureau of Prisons. 

For the CJ–36 form, 54 central reporters 

(two State jurisdictions in California 

and one each from the remaining States, 

the District of Columbia, the Federal 

Bureau of Prisons, and one local 

authority) responsible for keeping 

records on parolees will be asked to 

provide information for the following 

categories: 

(a) Whether the parole agency is 

located within the executive or judicial 

branch of government, whether it is a 

private organization under contract to a 

government agency; and whether the 

agency is administered by the 

Department of Corrections, a court, an 

independent agency or another parole 

agency; 

(b) As of June 30, 2006, the number 

of adult parolees under their 

jurisdiction; 

(c) As of June 30, 2006, the number 

of adult parolees under their 

jurisdiction who were supervised 

following a discretionary release, a 

mandatory release, a special conditional 

release, or other type of release from 

prison; 

(d) Whether the adult parole 

supervising agency also supervises 

either adult probationers or juveniles on 

probation or parole/aftercare, and the